Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: peptide therapeutics - Allostera Pharma

Drug Profile

Research programme: peptide therapeutics - Allostera Pharma

Alternative Names: APG 101.10; APG 2305

Latest Information Update: 30 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allostera Pharma
  • Class Peptides; Small molecules
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists; Interleukin 1 receptor antagonists; Interleukin 13 receptor antagonists; Interleukin 18 inhibitors; Interleukin 23 inhibitors; Interleukin 4 receptor antagonists; Tumour necrosis factor receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Age-related macular degeneration; Asthma; Cancer; Chronic obstructive pulmonary disease; Emphysema; Gout; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Type 2 diabetes mellitus

Most Recent Events

  • 08 Jul 2009 Early research in Age-related macular degeneration in Canada (PO)
  • 08 Jul 2009 Early research in Asthma in Canada (PO)
  • 08 Jul 2009 Early research in Chronic obstructive pulmonary disease in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top